A023910 Stock Overview
Engages in the manufacture and sale of therapeutic drugs in South Korea. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for A023910 from our risk checks.
Daihan Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩26,000.00 |
52 Week High | ₩29,650.00 |
52 Week Low | ₩23,750.00 |
Beta | 0.22 |
11 Month Change | 2.16% |
3 Month Change | -2.80% |
1 Year Change | -6.14% |
33 Year Change | -12.31% |
5 Year Change | -16.13% |
Change since IPO | 593.33% |
Recent News & Updates
Recent updates
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly
Mar 02Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Feb 09Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?
Jan 19What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?
Dec 18Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?
Nov 27Shareholder Returns
A023910 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 3.8% | -3.0% | 2.3% |
1Y | -6.1% | 6.3% | -3.8% |
Return vs Industry: A023910 underperformed the KR Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: A023910 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
A023910 volatility | |
---|---|
A023910 Average Weekly Movement | 2.2% |
Pharmaceuticals Industry Average Movement | 5.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in KR Market | 11.4% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A023910 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A023910's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1945 | n/a | Sungyoung Lee | www.daihan.com |
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions.
Daihan Pharmaceutical Co.,Ltd. Fundamentals Summary
A023910 fundamental statistics | |
---|---|
Market cap | ₩152.88b |
Earnings (TTM) | ₩30.67b |
Revenue (TTM) | ₩201.97b |
5.0x
P/E Ratio0.8x
P/S RatioIs A023910 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A023910 income statement (TTM) | |
---|---|
Revenue | ₩201.97b |
Cost of Revenue | ₩133.95b |
Gross Profit | ₩68.02b |
Other Expenses | ₩37.36b |
Earnings | ₩30.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.22k |
Gross Margin | 33.68% |
Net Profit Margin | 15.18% |
Debt/Equity Ratio | 0% |
How did A023910 perform over the long term?
See historical performance and comparison